KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 0.98

Study Rationale, Enrollment Characteristics, and Central Review of Clinical Stage: The INTACT Randomized Clinical Trial.

Parminder Singh, Melissa Plets, Jason Efsthathiou, Sameer G Jhavar, Catherine Tangen, Scott Delacroix, Carie Marquette, Kent W Mouw, Maged F Khalil, Leslie K Ballas, Sean Sachdev, Burles Avner Johnson, Ashesh Jani, Brian Cross, Petros Grivas, Jason Palopoli, Austin Kirchner, Xinglei Shen, Mamta Parikh, Adam Olson, Paul Mehan, Brian Costello, Monika Joshi, Siamak Daneshmand, Daniel Petrylak, Ian Thompson, Paul L Nguyen, Seth P Lerner

JAMA Netw Open 9(11) e2644122

PMID43037986
PMCIDPMC13775114
DOI10.1001/jamanetworkopen.2026.44122
发表日期2026-11-16
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
摘要

摘要

IMPORTANCE: Trimodality therapy (TMT) is an established bladder-preservation approach for muscle-invasive bladder cancer (MIBC). Accurate clinical staging remains challenging and may affect patient selection, trial design, and interpretation of outcomes. OBJECTIVE: To describe the design, accrual, and baseline characteristics of the Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (INTACT) trial and evaluate agreement between site-reported and centrally reviewed clinical stage and the prevalence of high-risk disease features. DESIGN, SETTING, AND PARTICIPANTS: INTACT is a phase 3 randomized clinical trial that enrolled patients with localized MIBC (stage cT2-T4aN0M0) at 136 US sites between April 2019 and March 2025. For this analysis, 243 patients with available source documentation were randomly selected by the SWOG Statistical Center for central clinical staging review. INTERVENTIONS: Patients were randomized to physician's choice of concurrent chemotherapy (cisplatin, gemcitabine, or 5-fluorouracil and mitomycin C) and radiotherapy (bladder only or small pelvis; 64-64.8 Gy), with or without atezolizumab (1200 mg intravenously every 3 weeks for 9 cycles). MAIN OUTCOMES AND MEASURES: The trial's primary end point is 3-year bladder-intact event-free survival, which is not reported in this analysis. Outcomes for the present analysis included trial accrual, clinical stage distribution, agreement between site-reported stage and the initial independent central reviewer, and prevalence of predefined high-risk features (carcinoma in situ, unilateral hydronephrosis, or tumor >5 cm). Agreement was assessed using Cohen κ and directional disagreement using the McNemar test. RESULTS: Among 485 randomized patients, the median (IQR) age was 73.8 (37.6-93.6) years, 384 (79.2%) were male, 16 (3.3%) were Asian, 33 (6.8%) were Black, and 419 (86.4%) were White. Site investigators classified 398 (82.1%) as stage cT2 and 87 (17.9%) as stage cT3 or T4a. Among 243 patients selected for central review, 201 (82.7%) had site-reported stage cT2 disease and 42 (17.3%) had stage cT3 or T4a disease. Agreement between site-reported stage and the initial independent central reviewer was moderate (κ = 0.48; 95% CI, 0.34-0.62). Of 201 site-reported stage cT2 cases, 24 (11.9%) were assigned stage cT3 or T4a by the central reviewer; of 42 site-reported stage cT3 or T4a cases, 15 (35.7%) were assigned stage cT2. Among patients with site-reported stage cT2 disease, 113 (56.2%) had at least 1 high-risk feature. Overall, 155 of 243 patients (63.8%) had at least 1 high-risk feature. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial, a pragmatic design facilitated accrual of 485 patients to a US bladder-preservation trial. Clinical staging showed moderate agreement between site investigators and independent central review, and more than half of patients classified as stage cT2 had additional high-risk features. These findings support standardized collection of clinical staging and high-risk disease characteristics in future bladder-preservation trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03775265.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。